X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7457) 7457
Book Review (619) 619
Publication (273) 273
Newsletter (17) 17
Newspaper Article (16) 16
Magazine Article (10) 10
Book Chapter (9) 9
Conference Proceeding (7) 7
Transcript (6) 6
Dissertation (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6795) 6795
index medicus (6716) 6716
female (4718) 4718
male (4686) 4686
vincristine - administration & dosage (3856) 3856
antineoplastic combined chemotherapy protocols - therapeutic use (3587) 3587
middle aged (3435) 3435
adult (3229) 3229
antineoplastic combined chemotherapy protocols - adverse effects (2985) 2985
vincristine - adverse effects (2963) 2963
oncology (2757) 2757
aged (2634) 2634
cyclophosphamide - administration & dosage (2351) 2351
doxorubicin - administration & dosage (2196) 2196
chemotherapy (2179) 2179
vincristine (1780) 1780
prednisone - administration & dosage (1719) 1719
adolescent (1685) 1685
vincristine - therapeutic use (1682) 1682
cyclophosphamide - adverse effects (1541) 1541
hematology (1475) 1475
doxorubicin - adverse effects (1435) 1435
treatment outcome (1396) 1396
antineoplastic combined chemotherapy protocols - administration & dosage (1313) 1313
cancer (1260) 1260
child (1255) 1255
prednisone - adverse effects (1238) 1238
child, preschool (1013) 1013
cyclophosphamide - therapeutic use (1004) 1004
abridged index medicus (980) 980
combined modality therapy (955) 955
prognosis (906) 906
etoposide - administration & dosage (883) 883
prednisone - therapeutic use (857) 857
methotrexate - administration & dosage (851) 851
cyclophosphamide (835) 835
doxorubicin - therapeutic use (818) 818
therapy (795) 795
retrospective studies (740) 740
disease-free survival (737) 737
lymphoma, non-hodgkin - drug therapy (731) 731
remission induction (729) 729
follow-up studies (716) 716
antineoplastic agents - adverse effects (715) 715
rituximab (708) 708
bleomycin - administration & dosage (693) 693
drug therapy, combination (690) 690
drug administration schedule (668) 668
neoplasm staging (664) 664
doxorubicin (660) 660
survival rate (643) 643
aged, 80 and over (642) 642
hodgkin disease - drug therapy (633) 633
infant (629) 629
survival analysis (617) 617
lymphomas (605) 605
lymphoma, large b-cell, diffuse - drug therapy (591) 591
methotrexate - adverse effects (577) 577
care and treatment (566) 566
time factors (541) 541
procarbazine - administration & dosage (536) 536
children (515) 515
pediatrics (506) 506
non-hodgkins-lymphoma (494) 494
bleomycin - adverse effects (493) 493
survival (492) 492
etoposide - adverse effects (487) 487
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (475) 475
risk factors (473) 473
cisplatin - administration & dosage (472) 472
antineoplastic agents - therapeutic use (467) 467
radiotherapy (456) 456
prospective studies (454) 454
animals (444) 444
lung neoplasms - drug therapy (431) 431
young adult (428) 428
cytarabine - administration & dosage (419) 419
prednisolone - administration & dosage (411) 411
medicine & public health (406) 406
procarbazine - adverse effects (406) 406
antineoplastic agents - administration & dosage (397) 397
lymphoma (397) 397
dexamethasone - administration & dosage (374) 374
etoposide (369) 369
prednisone (369) 369
trial (369) 369
clinical trials as topic (358) 358
dose-response relationship, drug (351) 351
pharmacology & pharmacy (333) 333
leukemia (331) 331
toxicity (326) 326
recurrence (308) 308
methotrexate - therapeutic use (306) 306
analysis (303) 303
carcinoma, small cell - drug therapy (300) 300
dacarbazine - administration & dosage (299) 299
drug therapy (292) 292
transplantation (291) 291
combination chemotherapy (290) 290
antineoplastic agents (289) 289
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6763) 6763
Japanese (174) 174
German (151) 151
French (140) 140
Spanish (64) 64
Chinese (53) 53
Russian (48) 48
Italian (40) 40
Polish (31) 31
Danish (8) 8
Hungarian (8) 8
Portuguese (6) 6
Czech (5) 5
Croatian (4) 4
Dutch (4) 4
Hebrew (4) 4
Serbian (3) 3
Swedish (3) 3
Slovak (2) 2
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 03/2018, Volume 19, Issue 3, pp. 683 - 687
The present study was designed to determine changes in spermatogenesis in adult mice after an intraperitoneal injection of vincristine. The effect of a GnRH... 
Chemotherapy drug | Spermatogony | GnRH | Seminiferous tubules | Vincristine | Cetrorelix | seminiferous tubules | vincristine | cetrorelix | spermatogony
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9999, pp. 1156 - 1164
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Adult | Female | Radiotherapy Dosage | Etoposide - adverse effects | Prednisone - adverse effects | Proportional Hazards Models | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3651 - 3658
Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in... 
TRIAL | MORTALITY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | INVOLVED-FIELD RADIATION | PEDIATRIC-PATIENTS | DISEASE | FOLLOW-UP | CHILDHOOD-CANCER SURVIVOR | NO RADIOTHERAPY | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 19, pp. 2944 - 2952
This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab(BR) vs a standard... 
REFRACTORY INDOLENT | THERAPY | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-II MULTICENTER | HEMATOLOGY | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Nausea - chemically induced | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Paresthesia - chemically induced | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Vomiting - chemically induced | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Alopecia - chemically induced | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus | 8 | Clinical Trials and Observations | 39 | 29
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2015, Volume 169, Issue 5, pp. 672 - 682
This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐ CC chemokine receptor 4... 
mogamulizumab | study | CCR | randomized phase | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | CCR4 | Randomized phase II study | randomized phase II study | adult T-cell leukaemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | RECEPTOR | LEUKEMIA/LYMPHOMA | HEMATOLOGY | EXPRESSION | ASSOCIATION | TRANSPLANTATION | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Index Medicus | Haematological Malignancy | Research Paper
Journal Article